Share on StockTwits

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) CEO Keith R. Leonard unloaded 8,925 shares of the company’s stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $39.47, for a total value of $352,269.75. The sale was disclosed in a document filed with the SEC, which is available at this link.

Shares of KYTHERA Biopharmaceuticals (NASDAQ:KYTH) traded down 2.67% on Thursday, hitting $39.03. The stock had a trading volume of 90,819 shares. KYTHERA Biopharmaceuticals has a 52-week low of $23.03 and a 52-week high of $56.36. The stock’s 50-day moving average is $35.59 and its 200-day moving average is $39.67. The company’s market cap is $884.3 million.

KYTHERA Biopharmaceuticals (NASDAQ:KYTH) last released its earnings data on Thursday, May 8th. The company reported ($3.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $2.51. Analysts expect that KYTHERA Biopharmaceuticals will post $-3.33 EPS for the current fiscal year.

KYTHERA Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.